21

2

Logo

BIOXIS Pharmaceuticals

Company | France

Primary tabs

About your organization

Bioxis Pharmaceuticals is developing MTI12, the world’s first Monophasic Tissular Inductor, using its proprietary chitosan technology that brings significant improvements to current dermal filler treatment. To bring MTI12 to market, the company has set up a fully integrated eco-system from research and development through raw materials manufacturing to production and distribution.

In addition to its MTI12 technology and in response to a huge demand for high quality crosslinked hyaluronic acid dermal fillers, Bioxis has developed CYTOSIAL, a complementary line of dermal fillers using its proprietary hyaluronic acid technology. Launched in April 2017.

Network (0)

There are no organizations in the network.

Recent activity

You are not connected

A certain number of contents are hidden from you and you do not benefit from the linking functionalities.

Log in or register to access to the entire contents and functionnalities. Subscription is quick and free.